AMD 3465 hexahydrobromidePotent and selective CXCR4 antagonist CAS# 185991-07-5 |
- AMD 3465
Catalog No.:BCC5181
CAS No.:185991-24-6
- Reparixin L-lysine salt
Catalog No.:BCC1886
CAS No.:266359-93-7
- SCH 527123
Catalog No.:BCC1932
CAS No.:473727-83-2
- AMD-070
Catalog No.:BCC1357
CAS No.:558447-26-0
- UNBS 5162
Catalog No.:BCC4008
CAS No.:956590-23-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 185991-07-5 | SDF | Download SDF |
PubChem ID | 9897616 | Appearance | Powder |
Formula | C24H44Br6N6 | M.Wt | 896.07 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GENZ-644494 hexahydrobromide | ||
Solubility | H2O : ≥ 38 mg/mL (42.41 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine;hexahydrobromide | ||
SMILES | C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CNCC3=CC=CC=N3.Br.Br.Br.Br.Br.Br | ||
Standard InChIKey | ARHBIBDGWDRBJH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H38N6.6BrH/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30;;;;;;/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2;6*1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent, selective CXCR4 antagonist; exhibits 8-fold higher affinity than AMD 3100. Inhibits SDF-1α-ligand binding (Ki = 41.7 nM). Potently inhibits HIV cell entry in vitro; causes leukocytosis and mobilizes haematopoietic stem cells in vivo. |
AMD 3465 hexahydrobromide Dilution Calculator
AMD 3465 hexahydrobromide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.116 mL | 5.5799 mL | 11.1598 mL | 22.3197 mL | 27.8996 mL |
5 mM | 0.2232 mL | 1.116 mL | 2.232 mL | 4.4639 mL | 5.5799 mL |
10 mM | 0.1116 mL | 0.558 mL | 1.116 mL | 2.232 mL | 2.79 mL |
50 mM | 0.0223 mL | 0.1116 mL | 0.2232 mL | 0.4464 mL | 0.558 mL |
100 mM | 0.0112 mL | 0.0558 mL | 0.1116 mL | 0.2232 mL | 0.279 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AMD 3465 6HBr(GENZ-644494) is a potent, selective CXCR4 antagonist; exhibits 8-fold higher affinity than AMD 3100; inhibits SDF-1α-ligand binding (Ki = 41.7 nM).
- H-Ile-OMe.HCl
Catalog No.:BCC2964
CAS No.:18598-74-8
- H-Cys-OMe.HCl
Catalog No.:BCC2905
CAS No.:18598-63-5
- Echinulin
Catalog No.:BCN1157
CAS No.:1859-87-6
- Pterodontic acid
Catalog No.:BCN1156
CAS No.:185845-89-0
- 2,3-Dihydroxypterodontic acid
Catalog No.:BCN1155
CAS No.:185821-32-3
- Viroallosecurinine
Catalog No.:BCN6743
CAS No.:1857-30-3
- BMS 961
Catalog No.:BCC7680
CAS No.:185629-22-5
- ONO 2506
Catalog No.:BCC7943
CAS No.:185517-21-9
- Timorsaponin C
Catalog No.:BCN2899
CAS No.:185432-00-2
- Corchoionoside C
Catalog No.:BCN1154
CAS No.:185414-25-9
- AF 12198
Catalog No.:BCC5812
CAS No.:185413-30-3
- O-Acetylethanolamine
Catalog No.:BCN1757
CAS No.:1854-30-4
- AMD 3465
Catalog No.:BCC5181
CAS No.:185991-24-6
- RS 79948 hydrochloride
Catalog No.:BCC6876
CAS No.:186002-54-0
- Kakuol
Catalog No.:BCN6455
CAS No.:18607-90-4
- Deacetylnimbin
Catalog No.:BCN4684
CAS No.:18609-16-0
- Quercetin-3-O-sophoroside
Catalog No.:BCN2771
CAS No.:18609-17-1
- 11alpha,12alpha-Epoxy-3beta,23-dihydroxy-30-norolean-20(29)-en-28,13beta-olide
Catalog No.:BCN1515
CAS No.:186140-36-3
- (-)-Anonaine
Catalog No.:BCN8235
CAS No.:1862-41-5
- H-Dapa-OH.HBr
Catalog No.:BCC2668
CAS No.:18635-45-5
- enantio-7(11)-Eudesmen-4-ol
Catalog No.:BCN1158
CAS No.:186374-63-0
- CP-91149
Catalog No.:BCC3757
CAS No.:186392-40-5
- CP 316819
Catalog No.:BCC6039
CAS No.:186392-43-8
- Psoralidin
Catalog No.:BCN5414
CAS No.:18642-23-4
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.[Pubmed:19540208]
Biochem Pharmacol. 2009 Oct 15;78(8):993-1000.
CXCR4 is widely expressed in multiple cell types, and is involved in neonatal development, hematopoiesis, and lymphocyte trafficking and homing. Disruption of the CXCL12/CXCR4 interaction has been implicated in stem cell mobilization. Additionally CXCR4 is a co-receptor for HIV. Selective small molecule antagonists of CXCR4 therefore have therapeutic potential. AMD3465 is an N-pyridinylmethylene monocyclam CXCR4 antagonist which can block infection of T-tropic, CXCR4-using HIV. Using the CCRF-CEM T-cell line which expresses CXCR4 we have demonstrated that AMD3465 is an antagonist of SDF-1 ligand binding (K(i) of 41.7+/-1.2nM), and inhibits SDF-1 mediated signaling as shown by inhibition of GTP binding, calcium flux, and inhibition of chemotaxis. AMD3465 is selective for CXCR4 and does not inhibit chemokine-stimulated calcium flux in cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7, nor does it inhibit binding of LTB(4) to its receptor, BLT1. The pharmacokinetics of AMD3465 was investigated in mice and dogs. Absorption was rapid following subcutaneous administration. AMD3465 was cleared from dog plasma in a biphasic manner with a terminal half-life of 1.56-4.63h. Comparison of exposure to the intravenous and subcutaneous doses indicated 100% bioavailability following subcutaneous administration. AMD3465 caused leukocytosis when administered subcutaneously in mice and dogs, with peak mobilization occurring between 0.5 and 1.5h following subcutaneous dosing in mice and with maximum peak plasma concentration of compound preceding peak mobilization in dogs, indicating that AMD3465 has the potential to mobilize hematopoietic stem cells. These data demonstrate the therapeutic potential for the CXCR4 antagonist AMD3465.
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.[Pubmed:17599916]
J Biol Chem. 2007 Sep 14;282(37):27354-65.
AMD3465 is a novel, nonpeptide CXCR4 antagonist and a potent inhibitor of HIV cell entry in that one of the four-nitrogen cyclam rings of the symmetrical, prototype bicyclam antagonist AMD3100 has been replaced by a two-nitrogen N-pyridinylmethylene moiety. This substitution induced an 8-fold higher affinity as determined against (125)I-12G5 monoclonal CXCR4 antibody binding, and a 22-fold higher potency in inhibition of CXCL12-induced signaling through phosphatidylinositol accumulation. Mutational mapping of AMD3465 and a series of analogs of this in a library of 23 mutants covering the main ligand binding pocket of the CXCR4 receptor demonstrated that the single cyclam ring of AMD3465 binds in the pocket around AspIV:20 (Asp(171)), in analogy with AMD3100, whereas the N-pyridinylmethylene moiety mimics the other cyclam ring through interactions with the two acidic anchor-point residues in transmembrane (TM)-VI (AspVI:23/Asp(262)) and TM-VII (GluVII:06/Glu(288)). Importantly, AMD3465 has picked up novel interaction sites, for example, His(281) located at the interface of extracellular loop 3 and TM-VII and HisIII:05 (His(113)) in the middle of the binding pocket. It is concluded that the simple N-pyridinylmethylene moiety of AMD3465 substitutes for one of the complex cyclam moieties of AMD3100 through an improved and in fact expanded interaction pattern mainly with residues located in the extracellular segments of TM-VI and -VII of the CXCR4 receptor. It is suggested that the remaining cyclam ring of AMD3465, which ensures the efficacious blocking of the receptor, in a similar manner can be replaced by chemical moieties allowing for, for example, oral bioavailability.